Géraldine Honnet moves to Sensorion from Généthon to become the company’s chief medical officer, bringing with her a number of years of experience working on gene therapies.
The biopharma company is not exclusively focused on gene therapies, as it also possesses small molecule therapies within its pipeline of treatments, with its lead drug candidate being SENS-401, a small molecule treatment in Phase II trials.
However, Sensorion possesses two preclinical gene therapies for Usher syndrome and Otoferlin deficiency, as well as holding an agreement with Institut Pasteur for the option to obtain exclusive licenses for further gene therapy candidates.
Before Généthon, where she also held the role of chief medical officer, Honnet spent time as medical director at Parexel International and as an international project manager for Janssen.
CEO of Sensorion, Nawal Ouzren, stated that gene therapy had become a ‘key pillar’ for the copan during 2019 and that Honnet’s appointment had been made due to her ‘extensive expertise’ in the area.